Grant: Proof of Principle Program - Phase I
University of Toronto
$160,000.00
Developing a Novel Therapeutic for Cushing's Syndrome
EF 2013-14
Résumé
Cushing's syndrome is a rare disease that refers to the combination of illnesses (obesity, diabetes, hypertension, osteoporosis and muscle wasting) resulting from sustained high levels of cortisol or other glucocorticoids. Cushing's syndrome is sub-divided into two categories, exogenous and endogenous, depending on the reason for the high cortisol. Exogenous Cushing's syndrome refers to the side effects associated with the use of glucocorticoid drugs that are prescribed to treat various inflammatory conditions including asthma, rheumatoid arthritis, and lupus or for immunosuppression after transplantation. Endogenous Cushing's syndrome refers to the disease resulting from high cortisol levels most commonly caused by a pituitary tumour (also sometimes referred to as Cushing's disease). Our laboratory recently identified a novel protein (LXRb) that is important in amplifying the glucocorticoid response. We have shown that inhibition of this protein in mice that have been treated short-term with glucocorticoid drugs (exogenous Cushing's) decreases the development of diabetes. Herein, we propose to use a whole body animal model of endogenous Cushing's disease (CRH-transgenic mice) to determine if our inhibitors can prevent osteoporosis and muscle wasting, two side effects associated with long-term exposure to high cortisol. These studies will establish whether mono-therapy with our LXRb inhibitors will prevent osteoporosis and muscle wasting, filling an unmet need for patients with Cushing's syndrome, and expanding our non-clinical proof-of-concept data package. Second, because Cushing's syndrome is a rare disease, it is of interest to large pharmaceutical companies that have orphan drug programs. By examining the effectiveness of the LXRb antagonists in this orphan condition, we hope to speed up the time needed to develop and get a new therapy to market, ultimately benefiting Canadians (and other patients around the world) that suffer from this rare syndrome.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
293898
Name
Cummins Carolyn L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Developing a Novel Therapeutic for Cushing's Syndrome
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cushing'S Syndrome; Diabetes; Drug Target; Glucocorticoid; Glucocorticoid Receptor; Liver X Receptor; Muscle Wasting; Obesity; Osteoporosis
Abstract
Cushing's syndrome is a rare disease that refers to the combination of illnesses (obesity, diabetes, hypertension, osteoporosis and muscle wasting) resulting from sustained high levels of cortisol or other glucocorticoids. Cushing's syndrome is sub-divided into two categories, exogenous and endogenous, depending on the reason for the high cortisol. Exogenous Cushing's syndrome refers to the side effects associated with the use of glucocorticoid drugs that are prescribed to treat various inflammatory conditions including asthma, rheumatoid arthritis, and lupus or for immunosuppression after transplantation. Endogenous Cushing's syndrome refers to the disease resulting from high cortisol levels most commonly caused by a pituitary tumour (also sometimes referred to as Cushing's disease). Our laboratory recently identified a novel protein (LXRb) that is important in amplifying the glucocorticoid response. We have shown that inhibition of this protein in mice that have been treated short-term with glucocorticoid drugs (exogenous Cushing's) decreases the development of diabetes. Herein, we propose to use a whole body animal model of endogenous Cushing's disease (CRH-transgenic mice) to determine if our inhibitors can prevent osteoporosis and muscle wasting, two side effects associated with long-term exposure to high cortisol. These studies will establish whether mono-therapy with our LXRb inhibitors will prevent osteoporosis and muscle wasting, filling an unmet need for patients with Cushing's syndrome, and expanding our non-clinical proof-of-concept data package. Second, because Cushing's syndrome is a rare disease, it is of interest to large pharmaceutical companies that have orphan drug programs. By examining the effectiveness of the LXRb antagonists in this orphan condition, we hope to speed up the time needed to develop and get a new therapy to market, ultimately benefiting Canadians (and other patients around the world) that suffer from this rare syndrome.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cummins, Carolyn L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~